欢迎分享，转载有版权, 快快登录 lingmed.net/reports 下载全文吧
本周灵麦医药给您推荐一款来自德国的治疗多动症（ADHD）的项目
注意缺陷多动障碍（ADHD），俗称多动症，儿童期常见的一类心理障碍，主要症状是注意力散涣或集中困难、活动量过多且自制力弱。LMP1087最初于2015年在德国上市，现已占据德国市场地46%的市场份额（位居第一位）以及24%的欧洲市场份额（暂居第二位）。至今，已有16个系统的临床试验可以证明其有效性。
2016年全球及中国ADHD市场情况及2022年未来市场预测
LMP1087项目背景，全球竞争格局及中国重点公司
Bang Bang Bang- Leading ADHD Brand in Germany
This week Lingmed shares with you a novel asset in the area of ADHD. Attention-deficit/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. LMP1087 has marketed in Germany in 2015 and occupied 46% market share (the leading brand) in Germany and 24% market share in Europe. Up to now, there are 16 clinical trials to show its efficacy and safety.
Worldwide and Chinese ADHD market analysis in 2016 and market forecast in 2022
The product profile, competitive landscape and leading companies of LMP1087
想要下载完整报告?
请登录 www.lingmed.net/reports
或点击下方“阅读原文”马上下载